Clinical trial
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
NCT00256880 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00256880 |
|---|---|
| Title | Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma |
| Official title | A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | GW786034 |
| Enrollment | 100 |
| Start date | Jan 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Nov 22, 2005 |
| Last update posted | Jan 18, 2017 |
| Countries | Australia, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: